Please login to the form below

Not currently logged in
Email:
Password:

Dermagraft

This page shows the latest Dermagraft news and features for those working in and with pharma, biotech and healthcare.

Shire pays record $350m to settle US kickback allegations

Shire pays record $350m to settle US kickback allegations

Shire pays record $350m to settle US kickback allegations. Charges centred around diabetic foot ulcer treatment Dermagraft, which it sold in 2014. ... The settlement also resolves allegations that Shire and ABH promoted Dermagraft for off-label uses.

Latest news

  • Shire to file Vyvanse for binge-eating in Q3 Shire to file Vyvanse for binge-eating in Q3

    Shire's restructuring drive has already seen it divest poorly-performing foot ulcer treatment Dermagraft last year, in addition to acquiring rare disease specialist Viropharma for $4.2bn, SARcode Bioscience for

  • Shire's ADHD drug fails in depression trial Shire's ADHD drug fails in depression trial

    Nevertheless the negative result is a blow for Shire, which announced just last month it expects to face a $650m loss on the sale of its ulcer treatment Dermagraft.

  • Shire faces $650m loss on Dermagraft sale Shire faces $650m loss on Dermagraft sale

    Shire faces $650m loss on Dermagraft sale. Sells struggling foot ulcer treatment to Organogenesis. ... Organogenesis now owns the rights to all Dermagraft assets, including patents, product inventory and certain manufacturing equipment.

  • Shire misses Q1 targets as Replagal sales fall Shire misses Q1 targets as Replagal sales fall

    Meanwhile, wound healing product Dermagraft fell 62 per cent to $19m thanks to a restructuring of Shire's commercial operations in regenerative medicine.

  • Improving the prospects for ATMPs in Europe

    Established products include Shire subsidiary Advanced Biohealing's Dermagraft, which is already generating sales of around $200m a year, and Novartis/Organogenesis' Apligraf, both of which are based on allogeneic cells

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    320. Shire/ Organogenesis. Divestment. Shire's sale of its Dermagraft assets acquired as part of Advanced BioHealing.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The Merck &Co divestment of Sirna is noted above but, this month, Shire announced the divestment of Dermagraft (a bioengineered skin substitution product for diabetic foot ulcers) to Organogenesis.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics